undamentalytics Newsletter
Sign in

Seres Therapeutics, Inc. cash flow statement

In fiscal 2025, Seres Therapeutics, Inc.'s operations generated $1.1m of cash; it spent $252,000 on capital projects, leaving free cash flow of $865,000.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4144−76−63−77−947−229−117−1491−51
Depreciation and amortisation147887676543
Stock-based pay101717178920253421119
Capital spending421521110108000
Free cash flow−4522−80−65−78−94−3−239−125−1491−51
Free cash flow after stock pay−556−98−81−86−103−23−264−159−170−10−60
Share buybacks——0—————————
Shares issued143———6124409700——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KRSA vs MCRBMCRB vs OVIDABSI vs MCRB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Seres Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Seres Therapeutics, Inc.